The research peptide industry has a contamination problem that standard testing does not detect.
When we established Park Place Peptides, one of our first projects was submitting products from established US research peptide vendors to our laboratory for the same six-parameter analysis we apply to our own compounds. We wanted to understand the baseline quality in the market we were entering.
The results were consistent — and concerning.
What We Found
Products from multiple high-volume distributors passed standard purity testing. HPLC-UV results showed ≥98% purity across the board. By the industry’s own quality standard, these were acceptable products.
When we applied bioburden testing (microbiological culture per USP <61>/<62>), a different picture emerged. Significant bacterial growth. Elevated colony-forming unit counts. Organisms identified by PCR that were consistent with manufacturing environment contamination — not synthesis byproducts, but environmental bacteria that entered the product during handling, filling, or storage.
Why Standard Testing Misses This
HPLC-UV purity testing measures chemical purity — the ratio of target compound to synthesis-related impurities. It does not detect biological contamination. A vial can contain 99% pure peptide and significant bacterial bioburden simultaneously. These are orthogonal measurements.
Endotoxin testing (LAL) detects gram-negative bacterial endotoxins specifically. It does not detect gram-positive organisms, fungal contamination, or viable bacteria that have not yet lysed and released endotoxin. We found products that were endotoxin-negative but culture-positive — the bacteria were alive and intact, so their endotoxin was still contained within cell walls.
Why This Matters for Research
Bacterial contamination introduces uncontrolled variables. Immune activation, inflammatory signaling, injection site reactions, and systemic effects that get attributed to the research compound rather than to the contaminants. Research data generated from contaminated compounds is confounded data — and the investigator has no way of knowing unless the product was screened before use.
This is why we built a six-parameter quality panel that includes bioburden, organism identification, endotoxin, and gram-negative screening alongside identity and purity. Purity is necessary. It is not sufficient.
Read our full findings → · See our testing protocol →
All compounds sold by Park Place Peptides are for research use only. Not for human consumption.